Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease

BACKGROUND: The major therapeutic benefit of hydroxyurea, the only FDA-approved pharmacologic treatment for sickle cell disease (SCD), is directly related to fetal hemoglobin (HbF) production that leads to significant reduction of morbidity and mortality. However, potential adverse effects such as i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pule, Gift Dineo, Mowla, Shaheen, Novitzky, Nicolas, Wonkam, Ambroise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824700/
https://www.ncbi.nlm.nih.gov/pubmed/27056246
http://dx.doi.org/10.1186/s40169-016-0092-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824700/
https://www.ncbi.nlm.nih.gov/pubmed/27056246
http://dx.doi.org/10.1186/s40169-016-0092-7

Ejemplares similares